Ageing is the single largest risk factor for the chronic conditions that erode quality of life. That is not rhetoric; it is the central observation of geroscience: the biological processes that constitute ageing – rather than isolated lifestyle choices or single genes – drive the rising incidence of cardiovascular disease, cancer, type 2 diabetes, dementia and frailty. Treating those processes is therefore the most efficient route to delay or prevent multiple diseases at once.

Over the past decade, ageing biology has morphed from metaphor to map. Twelve clearly identified interconnected processes collectively shift physiology from resilience to vulnerability. These mechanisms are measurable, and crucially, modifiable.

Longevity medicine (geromedicine) applies this biology to practice. It combines precision personalised risk-stratified prevention with targeted interventions that aim to slow – or in some domains partially reverse – aspects of biological ageing. The evidence base spans: (i) lifestyle “drugs” with molecular readouts (progressive resistance and zone-2 aerobic training that remodel mitochondrial and inflammatory pathways); (ii) nutrition patterns that influence nutrient-sensing and proteostasis; (iii) repurposed drugs and (iv) emerging therapeutics. The central thesis: target ageing biology to shift the entire disease curve.

Our position is straightforward. If ageing biology drives chronic disease, then measuring and modulating ageing biology should be routine from midlife onward. That means using validated clocks and phenotypes to quantify trajectory; correcting the reversible (sleep, glycaemic variability, inflammation, mitochondrial efficiency); and deploying science-backed therapeutics through structured, longitudinal programmes. The goal is not mythic immortality but practical compounding: more function per year, fewer bad years at the end.

In short – treat the cause, not the consequences.